Semi-Annual Consolidated Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7732463

Concept 2017-04-01 to
2017-09-30
As at
2017-09-30
As at
2017-03-31
As at
2016-09-30
2016-04-01 to
2016-09-30
As at
2016-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-38,213,000 JPY
-108,466,000 JPY
Depreciation
JPY
60,528,000 JPY
Impairment losses
576,000 JPY
JPY
Amortization of goodwill
JPY
4,545,000 JPY
Interest and dividend income
-637,000 JPY
-682,000 JPY
Interest expenses
966,000 JPY
1,083,000 JPY
Foreign exchange losses (gains)
-632,000 JPY
7,891,000 JPY
Decrease (increase) in trade receivables
27,616,000 JPY
32,512,000 JPY
Decrease (increase) in inventories
-11,902,000 JPY
-12,692,000 JPY
Increase (decrease) in trade payables
3,455,000 JPY
-2,472,000 JPY
Other, net
-4,819,000 JPY
11,582,000 JPY
Subtotal
58,069,000 JPY
-81,054,000 JPY
Interest and dividends received
634,000 JPY
649,000 JPY
Interest paid
-925,000 JPY
-1,433,000 JPY
Income taxes paid
-3,337,000 JPY
-4,768,000 JPY
Net cash provided by (used in) operating activities
54,441,000 JPY
-86,606,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-900,000 JPY
-387,583,000 JPY
Purchase of investment securities
JPY
-79,800,000 JPY
Other, net
JPY
-142,000 JPY
Net cash provided by (used in) investing activities
-9,900,000 JPY
-511,951,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
330,000,000 JPY
Repayments of long-term borrowings
-73,044,000 JPY
-65,044,000 JPY
Net cash provided by (used in) financing activities
-73,358,000 JPY
810,798,000 JPY
Other, net
-314,000 JPY
-5,000 JPY
Effect of exchange rate change on cash and cash equivalents
632,000 JPY
-2,705,000 JPY
Net increase (decrease) in cash and cash equivalents
-28,184,000 JPY
209,534,000 JPY
Cash and cash equivalents
2,493,918,000 JPY
2,522,102,000 JPY
1,101,450,000 JPY
891,915,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.